The clinical burden that motivates this push is substantial. Bladder cancer, the most common form of urothelial carcinoma, is characterized by high rates of late diagnosis and strikingly frequent recurrence, forcing patients into years of repeated surveillance procedures. Cystoscopy, the endoscopic examination of the bladder that remains the diagnostic gold standard, is uncomfortable, expensive and offers only a visual snapshot of the tumor at a single moment in time. Tissue biopsy, meanwhile, samples only a fragment of the lesion, leaving the considerable spatial heterogeneity of the disease hidden from view. Neither approach lends itself naturally to the kind of longitudinal monitoring that bladder cancer patients, who face lifelong recurrence risk, genuinely require. It is precisely these constraints, the review argues, that have created the opening for liquid biopsy to move from research curiosity to clinical mainstay.

At the heart of the liquid biopsy concept are three principal analytes: circulating tumor DNA, circulating tumor cells and extracellular vesicles. Circulating tumor DNA consists of short fragments of tumor genome shed into the bloodstream, carrying with them the mutations, copy number variations and methylation patterns that define the original malignancy. Because it can be sampled repeatedly through a simple blood draw, ctDNA offers a dynamic, real-time portrait of tumor burden and evolution. The review details how technological advances, including droplet digital PCR and next-generation sequencing, have progressively lowered the detection limits for these faint molecular signals, enabling clinicians to identify residual disease at levels far below what imaging or cytology can resolve.

Circulating tumor cells, the second pillar, provide something ctDNA cannot: intact living cells that retain their morphology, protein expression and functional behavior. These cells, which detach from the primary tumor and travel through the circulation, are thought to be the seeds of metastasis. Capturing and characterizing them allows researchers to interrogate the epithelial-to-mesenchymal transition, the process by which cancer cells acquire invasive and migratory properties, and to profile the cell surface markers that may predict how aggressive a given patient’s disease will become. The review emphasizes that CTC enumeration and molecular characterization hold particular promise for prognostic stratification, helping to separate patients at high risk of progression from those who may be spared aggressive intervention.

Extracellular vesicles, the third and perhaps most versatile analyte, are nanoscale membrane-bound particles released by tumor cells into their surroundings. Far from being cellular debris, these vesicles act as intercellular messengers, ferrying proteins, lipids and nucleic acids between cells and actively shaping the tumor microenvironment. Within them travel microRNAs, long non-coding RNAs and circular RNAs, a cargo of regulatory molecules whose signatures can reveal both the presence of cancer and the state of the immune response against it. The review also highlights tumor-educated platelets, blood platelets that have been reprogrammed by tumor-derived signals and whose RNA profiles offer an additional, largely tumor-independent window into disease status.

What unites these analytes is their application across the entire arc of cancer care. In early detection, urine-based and blood-based biomarker panels are being developed to identify urothelial carcinoma before it becomes symptomatic, potentially reducing dependence on repeated invasive surveillance in patients with a history of the disease. In prognostic stratification, the review consolidates evidence linking ctDNA levels, CTC counts and vesicle cargo to progression-free and overall survival, suggesting that a single blood draw could one day inform how intensively a newly diagnosed patient is treated. In treatment response monitoring, serial liquid biopsy measurements can reveal whether neoadjuvant chemotherapy is working within weeks of initiation, long before radiographic scans could show any change, allowing ineffective regimens to be abandoned and alternatives started sooner.

The review gives particular attention to the intersection of liquid biopsy with immunotherapy, an area of intense clinical interest in metastatic urothelial carcinoma. Immune checkpoint inhibitors have reshaped treatment for advanced disease, but only a subset of patients respond, and clinicians currently lack reliable tools to identify responders in advance. Liquid biopsy offers several routes into this problem: ctDNA dynamics during therapy appear to correlate with response and survival, while the molecular features of circulating analytes can be used for immunophenotyping, characterizing the inflammatory and immune landscape of the tumor without touching it. The authors argue that such non-invasive immunophenotyping could eventually guide the selection of patients for checkpoint inhibitor therapy and for emerging combinations, moving the field closer to truly individualized immunotherapy decisions.

None of this, the review is careful to stress, is yet a finished story. Significant challenges persist before liquid biopsy can be integrated routinely into bladder cancer management. Analytical hurdles include the low fraction of tumor-derived DNA in early disease, the lack of standardized protocols for sample collection, processing and quality control, and variability among the many sequencing and capture platforms now on the market. Clinical hurdles include the absence of large, prospective, multicenter validation trials demonstrating that liquid biopsy-guided decisions genuinely improve patient outcomes, and unresolved questions about which analyte, or which combination of analytes, delivers the greatest value for each clinical scenario. Cost and accessibility also remain concerns if the technology is to benefit patients beyond specialized academic centers.

The translational path forward, as the authors outline it, involves converging several emerging technologies. Machine learning algorithms are increasingly being applied to multi-analyte datasets to extract diagnostic and prognostic signals that no single marker could provide, and whole-genome sequencing approaches are expanding the range of detectable alterations beyond the hotspots targeted by conventional panels. The review envisions a future in which a bladder cancer patient’s trajectory, from initial suspicion through treatment and into long-term surveillance, is punctuated not by repeated cystoscopies but by serial molecular snapshots drawn from blood and urine, with minimal residual disease detected and treated before it ever becomes visible on a scan.

For a disease defined by recurrence and heterogeneity, the appeal of that vision is easy to understand. The review’s synthesis makes the case that the scientific groundwork, sensitive detection platforms, biologically informative analytes and accumulating clinical evidence, has largely been laid. What remains is the disciplined work of validation, standardization and integration into treatment guidelines. If that work succeeds, liquid biopsy could shift bladder cancer care from a reactive cycle of detection and resection toward a proactive, molecularly informed model of precision oncology, in which each patient’s therapy is continuously calibrated to the evolving biology of their tumor, sampled not with a scalpel but with a needle and a vial.

Subject of Research: Liquid biopsy biomarkers for early detection, monitoring and precision treatment of bladder cancer

Article Title: Liquid biopsy in bladder cancer: towards precision oncology

Article References: Chen, C., Yang, Y., Chen, Z., Li, X., Zhu, Y., Zhai, Y., Zheng, J., Dai, X., Zhou, J.-G., Ma, H., & Ye, X. (2026). Liquid biopsy in bladder cancer: towards precision oncology. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08892-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08892-7

Keywords: liquid biopsy, bladder cancer, urothelial carcinoma, circulating tumor DNA, circulating tumor cells, extracellular vesicles, precision oncology, minimal residual disease, immune checkpoint inhibitors, tumor-educated platelets, next-generation sequencing, biomarkers

HER2, or human epidermal growth factor receptor 2, is a well-known oncogene whose amplification or overexpression is associated with aggressive breast cancer phenotypes and a worse prognosis. Current clinical protocols rely heavily on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to classify tumors as HER2-positive or negative, guiding targeted therapies such as trastuzumab. However, borderline cases—those with equivocal HER2 expression—pose a diagnostic dilemma with significant clinical ramifications. In these ambiguous scenarios, therapeutic decisions can become uncertain, underscoring the urgency for more precise, minimally invasive biomarkers.

The new research pivots around uPA, a serine protease involved in extracellular matrix degradation and tumor invasion. Previously studied mostly in the context of metastasis, uPA’s serum levels have not been definitively linked to HER2 status until now. This study harnessed advanced quantitative assays to measure circulating uPA protein concentrations across a large panel of breast cancer patients, comparing these with tumor HER2 status confirmed by gold-standard techniques. The results were striking: patients with borderline HER2-expressing and HER2-positive tumors showed distinctly elevated serum uPA levels compared to those with HER2-negative counterparts.

These findings indicate that uPA does more than simply mark tumor invasiveness. It acts as a molecular beacon, reflecting the underlying oncogenic machinery that drives HER2-related tumor biology. By integrating uPA measurement into diagnostic workflows, clinicians could gain a dynamic and systemic readout of tumor aggressiveness, transcending limitations inherent in tissue biopsies. This could dramatically refine patient stratification, eliminating uncertainty for borderline cases and enabling timely initiation of HER2-targeted therapies or alternative intervention strategies.

Moreover, the method’s non-invasive nature offers significant advantages over conventional biopsy-based diagnostics. Blood draws for serum biomarker evaluation are safer, less painful, and can be repeated over time to monitor disease progression or response to treatment. This is particularly valuable in advanced-stage cancer management, where tissue access is challenging. The study’s methodological rigor, including robust controls and cross-validation across multiple institutions, lends strong credibility to the translational potential of uPA assays as companion diagnostics.

The interplay between uPA and HER2 signaling cascades also opens fascinating avenues for mechanistic exploration. Data suggest that HER2 upregulation may induce uPA expression via downstream pathways such as MAPK and PI3K/AKT, creating a feedback loop that potentiates tumor proliferation and invasiveness. Understanding these molecular circuits could facilitate the development of dual-modal therapies that concurrently target receptor tyrosine kinases and proteolytic networks, potentially overcoming resistance mechanisms that compromise current HER2-targeted drugs.

Furthermore, the study’s comprehensive profiling extended beyond breast cancer, including other tumor types with known HER2 expression such as gastric and ovarian cancers. The consistent elevation of serum uPA levels in HER2-positive cohorts regardless of tumor origin underscores the biomarker’s broad applicability. This could standardize HER2 assessment across multiple malignancies, impacting diagnostic algorithms and therapeutic choices far beyond breast oncology.

While the discovery heralds exciting clinical implications, the authors caution that larger longitudinal studies are necessary to validate the prognostic and predictive power of serum uPA. Integrating uPA measurement with emerging multiomic data, including proteomics and genomics, might yield composite biomarker panels that enhance specificity and sensitivity. Additionally, the cost-effectiveness and accessibility of these assays must be evaluated to facilitate widespread adoption within diverse healthcare settings.

This breakthrough dovetails with ongoing trends in precision oncology, where biomarker-driven treatment is rapidly evolving toward more personalized paradigms. The ability to differentiate borderline HER2 statuses with a simple blood test could drastically reduce misclassification rates, minimize overtreatment or undertreatment, and improve patient outcomes. Given the rising global incidence of breast cancer and the substantial clinical burden of HER2 ambiguity, the deployment of serum uPA monitoring could represent a paradigm shift with profound health-economic benefits.

In conclusion, López Mujica et al.’s work propels urokinase plasminogen activator from a niche research molecule into a potent clinical tool poised to transform HER2 cancer diagnostics. As multidisciplinary efforts bridge molecular biology, clinical oncology, and diagnostic innovation, this marker exemplifies how integrated science can overcome long-standing clinical challenges. Moving forward, the oncology community will keenly watch the translation of these findings into validated diagnostic kits, clinical trials, and ultimately, improved standard-of-care practices that personalize treatment and save lives.

The promise of uPA as a serum biomarker for differentiating complex HER2 statuses also beckons further research into its role in tumor microenvironment modulation and immune interactions. Understanding how uPA influences not just cancer cells but also stromal components including fibroblasts and immune infiltrates could broaden therapeutic targeting opportunities. Moreover, its measurable presence in circulation raises prospects for monitoring minimal residual disease and early relapse, areas of intense interest in cancer survivorship.

Notably, these insights arrive at a pivotal moment as novel HER2-targeted agents, including bispecific antibodies and antibody-drug conjugates, are entering clinical practice. Precise HER2 categorization will be critical to identifying patients most likely to benefit from these sophisticated treatments. Serum uPA could serve as a companion diagnostic that streamlines patient selection, thereby maximizing therapeutic efficacy while minimizing unnecessary exposure to toxicities.

As the translational journey unfolds, collaboration between molecular scientists, clinicians, and diagnostic developers will be essential to optimize assay design, interpretive criteria, and clinical protocols. Real-world evidence gathered from prospective cohorts and routine clinical use will refine the biomarker’s utility and uncover further nuances. Importantly, patient engagement and education will be vital to ensure understanding and acceptance of biomarker-based diagnostics as part of individualized cancer care.

In sum, this study underscores the evolving landscape where serum biomarkers complement tissue-based pathology, advancing a more nuanced and clinically actionable understanding of cancer biology. By demystifying the borderline HER2 expression conundrum, serum urokinase plasminogen activator emerges as a compelling beacon guiding precision oncology into its next era.

Subject of Research: Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.

Article Title: Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.

Article References:
López Mujica, M.E.J., Boonkaew, S., Christensen, N.L. et al. Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03471-5

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03471-5

Cancer has long been recognized as a disease of the genome, characterized by mutations that drive uncontrolled cell growth and metastasis. Traditional biopsy methods provide a snapshot of the tumor’s genetic landscape at a fixed point in time, which, while informative, is inherently limited by tumor heterogeneity and spatial sampling constraints. ctDNA, fragments of tumor-derived DNA circulating freely in the bloodstream, circumvent these limitations by offering a minimally invasive, real-time biomarker that reflects the genomic complexity and evolution of cancers. SERENA-6 leverages this concept, employing serial ctDNA measurements to monitor tumor dynamics with unprecedented resolution.

The clinical implications of this approach are profound. By conducting dynamic ctDNA assessments, clinicians can detect emerging resistance mutations long before they manifest as radiographic progression or symptomatic relapse. This proactive insight enables timely treatment modifications, shifting the paradigm from reactive to preemptive oncology. SERENA-6’s methodology involves frequent blood draws analyzed through ultra-sensitive next-generation sequencing assays, capable of detecting minute variants at allele frequencies as low as 0.01%. This sensitivity is critical for capturing early shifts in the tumor’s molecular profile.

A key innovation of SERENA-6 lies in its real-time data integration. The trial employs a sophisticated bioinformatics pipeline that processes ctDNA data within hours, feeding results into clinical decision-making frameworks. This rapid turnaround transforms ctDNA from a purely diagnostic tool into a dynamic companion biomarker, guiding adaptive treatment algorithms. The study’s design emphasizes iterative therapy adjustments informed by evolving ctDNA signatures, a concept reflecting the tumor’s Darwinian evolution under selective therapeutic pressures.

The clinical trial encompassed diverse malignancies, including non-small cell lung cancer, colorectal carcinoma, and breast cancer—tumor types known for their molecular heterogeneity and propensity for resistance. Patients underwent baseline tissue biopsies alongside initial ctDNA profiling to establish concordance and ground truth. Subsequent serial ctDNA analyses enabled the detection of novel mutations, clonal expansions, and molecular relapse. This iterative approach allowed oncologists to tailor targeted agents, immunotherapies, or combination regimens more precisely than standard protocols permit.

One notable insight from SERENA-6 was the temporal discordance between molecular and radiologic responses. In many cases, ctDNA clearance preceded clinical remission by weeks to months, highlighting ctDNA’s potential as an early surrogate marker of therapeutic efficacy. Conversely, rising ctDNA levels frequently foreshadowed disease progression well before conventional imaging captured tumor burden increases. These findings underscore the potential of ctDNA to serve as an early warning system, optimizing treatment timing and potentially improving patient outcomes.

Beyond mutation tracking, SERENA-6 explored ctDNA quantitative dynamics as predictors of tumor burden and response kinetics. Mathematical modeling of ctDNA fragment abundance correlated with tumor size and growth rates, offering non-invasive metrics that parallel or even outperform imaging modalities. These quantitative insights provide clinicians with a more nuanced understanding of tumor biology and treatment impact, fostering personalized care strategies.

The trial also confronted several technical challenges inherent in ctDNA analysis. Biological variables such as DNA fragmentation patterns, clearance rates, and the influence of non-tumor DNA backgrounds demand rigorous assay standardization. SERENA-6 addressed these by employing multiple orthogonal sequencing approaches and validating assays across independent laboratories to ensure reproducibility. The precision of variant calling and error suppression techniques were critical to confidently distinguishing true mutations from artifacts—a necessary step for clinical application.

Importantly, SERENA-6 demonstrated the feasibility of integrating dynamic ctDNA monitoring into routine clinical workflows. Patient adherence to serial blood draws was high, and clinicians embraced the real-time data to guide complex therapeutic decisions. The trial laid the groundwork for larger, multi-center studies to validate outcome benefits and cost-effectiveness. The potential to reduce reliance on invasive biopsies and costly imaging presents an attractive economic incentive alongside clinical advantages.

Ethical considerations around genomic data privacy, patient consent, and equitable access to ctDNA testing were also addressed within the study framework. As precision oncology increasingly relies on molecular monitoring, frameworks ensuring responsible data stewardship become imperative. SERENA-6 exemplifies how technology, clinical medicine, and ethics can align to push the boundaries of personalized care.

Looking ahead, the implications of SERENA-6 ripple beyond direct patient care. The trial’s methodology offers a blueprint for adaptive trial designs that incorporate molecular feedback loops, accelerating drug development and biomarker discovery. By dynamically profiling tumor evolution, researchers can identify resistance pathways and novel therapeutic targets in near real time, shortening the drug development pipeline and enhancing translational research synergy.

As ctDNA technologies continue to mature, integration with other ‘omics platforms—such as proteomics, transcriptomics, and metabolomics—promises to deepen biological insight and therapeutic precision. Furthermore, emerging machine learning algorithms poised to analyze large volumes of molecular data may sharpen predictive models, enabling truly personalized, dynamic treatment regimens. SERENA-6 represents a seminal step toward such an integrative, data-driven oncology future.

In summary, SERENA-6 underscores the transformative potential of dynamic ctDNA assessment in revolutionizing precision cancer medicine. By capturing the fluid genomic landscape of tumors, this approach empowers clinicians to anticipate and circumvent therapeutic resistance, tailor interventions more precisely, and monitor disease course non-invasively. As this paradigm gains traction, it promises to redefine standards of cancer care, bringing us closer to the ultimate goal of durable remissions and personalized cures.

Subject of Research: Dynamic circulating tumor DNA (ctDNA) assessment in precision oncology and its impact on cancer treatment adaptation

Article Title: SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine

Article References:
Medford, A.J., Wander, S.A. SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine.
Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01066-2

Image Credits: AI Generated